Leap Therapeutics (LPTX) Lowered to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a buy rating to a hold rating in a report released on Thursday morning.

According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “

Shares of Leap Therapeutics (LPTX) traded down $0.02 during trading hours on Thursday, hitting $6.30. 50,120 shares of the stock traded hands, compared to its average volume of 65,457. The stock has a market cap of $77.83 and a P/E ratio of -1.82. Leap Therapeutics has a twelve month low of $4.90 and a twelve month high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.11). sell-side analysts predict that Leap Therapeutics will post -3.63 earnings per share for the current fiscal year.

In other Leap Therapeutics news, COO Augustine Lawlor purchased 1,057,769 shares of Leap Therapeutics stock in a transaction that occurred on Tuesday, November 14th. The stock was purchased at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 58.40% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/07/leap-therapeutics-lptx-lowered-to-hold-at-zacks-investment-research.html.

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Leap Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Leap Therapeutics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit